MEDIPAL HOLDINGS CORP.
Research MEDIPAL HOLDINGS CORP. (59Z) on Bullrun: valuation model: 19.3% undervalued, market cap EUR 2.82B, P/E 12.3, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker59Z
- ExchangeF
- CountryJapan
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyEUR
- Valuation signal19.3% undervalued
- Market capEUR 2.82B
- P/E12.3
- Dividend yield2.6%
- Financial periodFY2025
- RevenueEUR 3.67T
- Revenue growth3.2%
- Net incomeEUR 40.28B
- Free cash flowEUR 48.13B
- Gross margin7.0%
Valuation Snapshot
Bullrun's latest valuation model marks MEDIPAL HOLDINGS CORP. as 19.3% undervalued; latest market cap is EUR 2.82B; P/E is 12.3; dividend yield is 2.6%.
About MEDIPAL HOLDINGS CORP.
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products.
Frequently asked questions
Is MEDIPAL HOLDINGS CORP. overvalued or undervalued?
Bullrun's valuation model currently marks MEDIPAL HOLDINGS CORP. as 19.3% undervalued.
What is MEDIPAL HOLDINGS CORP.'s market cap?
MEDIPAL HOLDINGS CORP.'s market capitalization is EUR 2.82B.
What is MEDIPAL HOLDINGS CORP.'s P/E ratio?
MEDIPAL HOLDINGS CORP.'s price-to-earnings (P/E) ratio is 12.3.
Does MEDIPAL HOLDINGS CORP. pay a dividend?
MEDIPAL HOLDINGS CORP. has a dividend yield of 2.6%.
What does MEDIPAL HOLDINGS CORP. do?
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the...